Journal
EUROPEAN HEART JOURNAL
Volume 22, Issue 24, Pages 2262-2266Publisher
W B SAUNDERS CO LTD
DOI: 10.1053/euhj.2001.2692
Keywords
beta-fibrinogen promoter gene; myocardial infarction; stroke; venous thrombosis; cardiovascular risk
Categories
Funding
- NHLBI NIH HHS [HL58755] Funding Source: Medline
Ask authors/readers for more resources
Aim Polymorphisms in the promoter region of the beta -fibrinogen gene are associated with increased plasma fibrinogen levels. We investigated whether the distribution of the C148T polymorphism is associated with an increase in cardiovascular risk. Methods and Results In a nested case-control design. the distribution of the C148T pol,morphism was investigated among 751 participants in the Physicians' Health Stud Oo subsequently developed myocardial infarction, stroke or venous thromboembolism (cases) and among 751 age- and smoking-matched controls over follow-up of 8.6 bears. Frequency of the T allele was similar among men who hud myocardial infarction (22.7%. P=0.5). stroke (18.4%, P=0.2) or venous thromboembolism (17.0%, P=0.1) compared with those with no cardiovascular events (21.5%). The relative risk for any vascular event among men homozygous or heterozygous for the T allele compared with men homozygous for the C allele was 0.94 (95% CI 0.70-1.16). We found no evidence of an association bem een the T allele and myocardial infarction (relative risk 1.06; 95% CI 0.82-1.36), stroke (0.87, 0.63-1.21) or venous thromboembolism (0.75: 0.51-1.08). Analysis adjusted for aspirin use and traditional cardiovascular risk factors had no significant effect oil these findings. Conclusion In a large prospective cohort, carriage of the T allele for the C148T Mutation in the beta -Fibrinogen promoter gene was not associated with an increased subsequent risk, of cardiovascular events. (C) 2001 The European Society of Cardiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available